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Catalase1. Introduction
Although most of the drugs for tuberculosis were discovered
N50 years ago, TB accounts for about 1.4 million deaths every year
(Zumla et al., 2013). The majority of the TB cases are treatable with
the current long and complex regimen of drugs, although the lack of ad-
herence due to adverse effect is not unusual, leading to suboptimal re-
sponses and rising incidences of M(X)DR cases worldwide. In the last
40 years, only two new drugs have been approved for the treatment
of MDR-TB under specific conditions: bedaquiline and delamanid
(Andries et al., 2005; Thakare et al., 2015). Thus, there is a critical
need for the development of drugs with shorter, simpler regimens asOchoa 2, 28760 Tres Cantos,
oza-Losana).
. This is an open access article underwell as novel mechanisms of action that can be used for treatment of
drug-resistant forms of the disease.
Both target-based (Makarov et al., 2009) and phenotypic screening
(Ballell et al., 2013; Lechartier et al., 2014; Mak et al., 2012; Pethe et
al., 2010) approaches have been employed for the identification of anti-
tubercular drug leads. While a limited but significant number of exam-
ples exist for the latter (Abrahams et al., 2012; Makarov et al., 2009;
Remuinan et al., 2013), target-based approaches have encountered
very limited success as previously demonstrated in the antibacterial
field (Abrahams et al., 2012; Payne et al., 2007). Rather than invalidating
the approach per se, this situation highlights the disconnection between
concepts like genetic validation of target essentiality and the amenabil-
ity of that target for drug discovery. A deeper understanding of system
biology and themechanisms underlying antibiotic killing are important
for the discovery of new antimicrobial therapies through target-based
approaches. Additionally, for reasons that are not always obvious,the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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ample, protein and cell wall bio-synthesis and DNA gyrase have deliv-
ered multiple classes of published leads and marketed drugs, whereas
there are no known inhibitors for many other essential gene products,
despite a long history of antibacterial research (Kohanski et al., 2010).
In the antitubercular field, only a very limited number of targets such
as InhA, RpoB, DNA Gyrase, ATP synthase, and DprE1 have been shown
to be behind the action of potent bactericidal drugs or promising leads.
Isoniazid is a frontline anti-TB drug targeting InhA and is an essential
component of TB treatment regimen. Despite the seemingly simple
structure of INH, its mode of action has remained elusive for many
years (Vilcheze and Jacobs, 2007). INH penetrates the tubercle bacilli
by passive diffusion and is activated by the bacterial anti-oxidant en-
zyme KatG to a range of reactive species and isonicotinic acid. Relevant
reactive species form adducts with nicotinamide adenine dinucleotide
(NAD), which are able to interferewith NAD-utilizing enzymes, primar-
ily the enoyl-ACP reductase encoded by the inhA gene, leading to the
blockage of mycolic acid synthesis and delivering the lethal blow to M.
tuberculosis. The dependency on KatG activation for INH-mediated kill-
ing is also the source of the main clinical weakness associated with the
use of INH, as between 40% and 95% of INH-resistant MTB clinical iso-
lates have mutations in katG, leading to decreased activation of INH to
its active form (Hazbon et al., 2006; Seifert et al., 2015). While muta-
tions are also detected in clinical isolates in the inhA promoter region,
these can be successfully treated in most instances by increasing the
dose of isoniazid.
Different classes of direct InhA inhibitors have been identified previ-
ously using high-throughput screening, Encoded Library Technology,
and in silico design strategies (Lu et al., 2010; Manjunatha et al., 2015;
Pan and Tonge, 2012; Shirude et al., 2013; Sink et al., 2015; Vilcheze
et al., 2011; Encinas et al., 2014). Additionally, natural product
pyridomycin has been found to operate via InhA inhibition (Hartkoorn
et al., 2012; Lu et al., 2010). Most of these tended to show a lack of cor-
relation between enzymatic inhibition and whole-cell activity, have
moderate potencies, narrow selectivity windows or poor absorption,
distribution, metabolism, and excretion (ADME) properties, making
them unsuitable for further progression as drug leads.
GlaxoSmithKline (GSK), under the sponsorship of the TB Alliance,
has carried out a screen against InhA using the GSK compound collec-
tion and has identified the thiadiazole series as the most promising an-
titubercular family. In this study,we present thenovel and selective lead
compound and its attractive antitubercular properties.
2. Materials and methods
The human biological samples were sourced ethically and their re-
search use was according to the terms of the informed consent.
All animal studies were ethically reviewed and carried out in accor-
dance with European Directive 2010/63/EU and the GSK Policy on the
Care, Welfare and Treatment of Animals.
2.1. Compound Synthesis
GSK613 and GSK625 were obtained from commercial sources.
GSK693 was synthesized as described in the patent (Castro-Pichel et
al., 2012). Optical rotations were measured on a Rudolph AUTOPOL V
polarimeter at room temperature using a cell of 0.5 dm. 1H NMR spectra
were recorded on a Bruker DPX 400MHz NMR spectrometer. Measure-
ments were made at a temperature of 295 K, and are reported in ppm
using tetramethylsilane or solvent as an internal standard (DMSO-d6
at 2.50 ppm). The coupling constants (J) are given in Hz, and the split-
ting patterns are designated as follows: s, singlet; bs, broad singlet; d,
doublet; and m, multiplet. 13C NMR spectra were recorded on a Bruker
DPX 400 spectrometer at 295 K and are reported in ppm using solvent
as an internal standard (DMSO-d6 at 39.5 ppm). Analytical purity was
≥95%, as determined by 1H-NMR and HPLC analysis. Positive ion massspectra were acquired using a QSTAR Elite (AB Sciex Instruments)
mass spectrometer, equipped with a turbospray source, over a mass
range of 250–700, with a scan time of 1 s. The elemental composition
was calculated using Analyst QS 2.0 software.
(S)-1-(4-methylthiazol-2-yl)-1-(5-((1-((2-methylthiazol-4-
yl)methyl)-1H-pyrazol-3-yl)amino)-1,3,4-thiadiazol-2-yl)ethanol
(GSK693): [α]D20 = +119 (c = 1, MeOH). 1H NMR (300 MHz, DMSO-
d6): δ ppm 10.93 (bs, 1H, −NH), 7.75 (d, J = 2.20 Hz, 1H), 7.38 (bs,
1H), 7.33 (s, 1H,−OH), 7.28–7.29 (m, 1H), 6.03 (d, J = 2.27 Hz, 1H),
5.32 (s, 2H), 2.68 (s, 3H), 2.37 (s, 3H), 2.02 (d, J = 7.03 Hz, 3H). 13C-
NMR (100 MHz, DMSO-d6): δ ppm: 17.38, 19.18, 28.77, 51.32, 74.67,
94.29, 115.29, 117.15, 132.43, 148.65, 151.73, 152.42,156.50, 164.66,
166.28, 175.79. HRMS (m/z): [M + H]+ calcd. For C16H17N7OS3,
420.0730; found, 420.0717.2.2. Bacterial strains and culture
M. tuberculosis H37Rv, Mycobacterium smegmatismc2155 (Snapper
et al., 1990), and Mycobacterium bovis BCG Pasteur (Institut Pasteur)
were grown at 37 °C in Middlebrook 7H9 broth (Difco) supplemented
with 0.025% Tween 80 and 10% albumin–dextrose–catalase (ADC)
or on Middlebrook 7H10 plates supplemented with 10% oleic acid–
albumin–dextrose–catalase (OADC). Cell-free extracts were done
in 7H9 (Difco) supplemented with 100 ml of 10× AS solution (5%
albumin solution in salt: 10 mg albumin, 1.7 mg NaCl in 200 ml
water), 2.5 ml of 10% Tween 80 solution, and 0.1% carbon substrate
(acetamide, succinate, or glucose). Escherichia coli DH5αwas grown in
LB broth (LB).2.3. DNA manipulation, plasmids, and transformation
Generalmolecular biology procedureswere used as described previ-
ously (Green and Sambrook, 2012) or following the manufacturer in-
structions. E. coli DH5α, M. smegmatis mc2155, and M. bovis BCG
competent cells were prepared for electroporation as described previ-
ously (Goude et al., 2015; Green and Sambrook, 2012).2.4. Enzymatic purification of InhA
The plasmids were transformed into BL21(DE3) E. coli cells for pro-
tein overexpression. Cells carrying InhA overexpression plasmid were
cultured overnight in LB broth media together with 100 μg/ml ampicil-
lin at 37 °C with continuous shaking at 220 rpm. Then a 1% dilution of
the inoculum was made (10 ml of the starter culture into 4 × 1 l) in
LB broth media with 100 μg/ml ampicillin, and flasks were incubated
till the OD600 reached 0.7. Cells were induced with 0.5 mM IPTG at
30–32 °C for 3 h, harvested and resuspended for lysis in 100ml total vol-
ume of 10% glycerol, 25 mM Tris pH 8.0, and 2 mM DTT (freshly made)
at 4 °C. Cells were then sonicated 4 × 15 s at maximum amplitude with
45 s incubation on ice between pulses andfinally centrifuged at 30.000 g
at 4 °C for 1 h.
The supernatants were loaded on 6-ml Resource Q columns, which
were pre-equilibrated with 25 mM Tris–HCl pH 8.5, 2 mM DTT. Frac-
tions (2.5 ml) were collected over 20 column volumes (gradient of 0–
200 mM NaCl, 25 mM Tris–HCl pH 8.2, 2 mM DTT). The fractions were
run out on an SDS–PAGE gel and stainedwith Coomassie. Themost con-
centrated ones were selected and pooled to run on a Superdex 16/60
SEC to help decontaminate. The column was equilibrated with 25 mM
Tris–HCl pH 8.0, 2 mM DTT, and the pooled fractions were applied to
the column at 0.12 ml/min/1 ml fractions were collected in the follow-
ing buffer: 20mMTris–HCl pH 8.0, 2 mMDTT, 0.15MNaCl. The column
was run overnight, the fractions were checked by SDS–PAGE, and activ-
ity was verified by enzymatic assay.
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The trans-2-enoyl-ACP reductase enzyme ofM. tuberculosis catalyzes
the last step in the elongation cycle of the FAS-II pathway and reduces
the 2.3 double bond of trans-2-enoyl-ACP in a NADH-dependent man-
ner. High-throughput screening (HTS) and led optimization (LO) bio-
chemical assays are based in the oxidation of the cofactor in the
presence of dodecenoyl-CoA.
InhA inhibition by file compounds in a high-throughput format was
assessed using a substrate-induced quenching (SIQ) assay as described
previously (Vazquez et al., 2006). Reaction mixtures (3 μl) containing
100 μM test compound, 150 μM dodecenoyl-CoA, 100 μM NAD+,
30 μM NADH, 10 nM resorufin, 0.2% w/v pluronic acid F-127, 10 nM
resorufin, 0.01% BSA, 1%DMSO, and 1.25 nM InhA in 30mMPIPES buffer
at pH6.8were incubated in glass-bottom1536-well plates for 1 h at 20 °
C and 95% relative humidity. Plates were then read in a confocal micro-
scope (4-Channel Reader, Evotec Technologies) using 1D-FIDA settings
with beamscanner, Nd:Yag 532 nm excitation with a laser power of
150 μW for 200 ms/well. Confocal FLINT data from each screening
plate were normalized against control wells containing reaction mix-
tures in the absence of test compounds (high controls) and in the ab-
sence of enzyme (low controls). Assay quality was monitored for each
plate using the Z′ factor (Zhang et al., 1999) and the inhibition observed
in additional control wells containing a known inhibitor at its IC50. In
order to identify and discard signal quenchers, each plate was pre-
read before addition of enzyme.
Enzymatic activity to support LO phase was measured
fluorimetrically by following NADH oxidation at λexc = 340 nm and
λem = 480 nm, using 50 μM NADH and 50 μM 2-trans-dodecenoyl-
CoA (DDCoA) as substrates. Dose–response experiments to determine
IC50 were performed using 5 nM InhA, percentage of remaining enzy-
matic activity (%AR) at different compound concentrations were calcu-
lated with the next formula [%AR = 100*((sample − control 2) /
(control 1 − control 2))] where sample is the enzymatic activity for
each compound concentration, control 1 is enzyme activity in absence
of any compound, and control 2 is NADH oxidation in absence of en-
zyme; IC50 was calculated fitting %AR to a 2-parameter equation
[%AR= 100% / (1+ (compound conc / IC50)^s)], where s is a slope fac-
tor; IC50was calculated using GraFit 5.0.12 software (Eritacus Software
Ltd.). All reactions were run in 30 mM PIPES buffer, pH 6.8, at 25 °C.
2.6. Crystallization, data collection, and processing
The InhA:GSK625 complex was crystallized using the hanging drop
method; 0.2 mM InhA, 2 mM NAD+, and 2 mM GSK625 that was dis-
solved in 100% DMSO were incubated at room temperature for
~20 min and screened against sparse-matrix crystallization conditions.
The crystals were obtained in 1.1 M sodium malonate, 0.1 M HEPES
pH 7.0, and 0.5% (v/v) Jeffamine ED-2001 pH 7.0.
The diffraction data were collected at home source, at 120 K under
cryoprotection by a Rigaku Raxis detector coupled to anX-ray generator
with a rotating copper anode (λ= 1.541 Å). Data were processed by
Denzo and Scalepack software packages (Otwinowski and Minor,
1997). Crystals of the InhA:NAD+:GSK625 complex belonged to the
P212121 space group with four molecules in the ASU. InhA:GSK625
structure was solved by molecular replacement using the PDB entry
1ENY as a search model. The structure was built by Coot and further re-
fined by Phenix (Adams et al., 2010) yielding a finalmodel with Rwork=
20% and Rfree = 23%. Data processing statistics are given in Supplemen-
tary Table 1. PDB ID 1BVR.
2.7. Cloning and overexpression of InhA
Double digestionwith BglII and BamHI liberatesM. smegmatis andM.
tuberculosis inhA genes from plamids pATB15 and pATB14 (Parish et al.,
1997), respectively. The 918- and 917-bp fragments were cloned intopATB45 previously linearized by BamHI digestion. Ligations were per-
formed into E. coli DH5α. The final plasmids were verified by enzymatic
fragments analysis and both inhA genes were sequenced. Sequencing
was carried out with using the dideoxy chain-termination procedure
and reagents from Applied Biosystems (dRhodamine Terminator Cycle
Sequencing Ready Reaction kit) in an ABI Prism 310 automated DNA se-
quencer (Applied Biosystems). The electroporation of M. smegmatis
mc2155 and M. bovis BCG was carried out according to the method of
(Snapper et al., 1990), and transformantswere selected onMiddlebrook
7H10 plates supplemented with 10% OADC and hygromycin 50 μg/ml.
Transformant verifications were made by colony PCR by using the
PuRe Taq Ready-To-Go PCR Beads kit (GE Healthcare Life Sciences)
with the primers colony PCR 1 and 2. The sequences of the primers
were as follows: Primer colony 1, 5′-AATCCAAAGTTCAAACGAGGGG-
3′; Primer colony 2, 5′-CCACCACCCGATAAGAGAAAGG-3′. The following
thermocycler parameters were used: an initial denaturation step of
5 min at 94 °C, followed by 35 cycles of 30 s at 94 °C, 30 s at 62 °C and
3 min at 72 °C, and ending with a final elongation step of 10 min at
72 °C.
Protein expression levels were followed by SDS–PAGE. Cell-free ex-
tracts were obtained from M. smegmatis mc2155 and M. bovis BCG by
growing them in 500 ml Middlebrook 7H9 broth with 0.025% Tween
80 and 10% ADC (1 l conical flask) to log phase (OD 600 nm≈ 0.6) har-
vested by centrifugation (5000 rpm for 5min) and resuspended in 5ml
sterile distilled water. A quantity 0.5 ml of M. smegmatis mc2155 cells
was used to inoculate 250 conical flasks containing 100mlminimalme-
dium with either acetamide 1%, succinate 0.1%, or succinate 0.1% plus
acetamide 1%. A quantity 0.5 ml ofM. bovis BCG cells was used to inoc-
ulate 250ml conical flasks containing 100mlminimal mediumwith ei-
ther acetate 0.1%, acetate 0.1% plus acetamide 1%, ADC 10% or ADC 10%
plus acetamide 1%. Cultureswere incubated at 37 °C and harvested after
24 h (M. smegmatismc2155) or 7 days (M. bovis BCG).
Cell-free extracts were prepared from both cultures using the Mini-
BeadBeater (Biospec Products): 50 ml bacterial cells, resuspended in
1 ml 50 mM HEPES/KOH pH 7.5, 10 mMMgCl2, 60 mM NH4Cl, 10% (v/
v) glycerol, and 5 mM 2-mercaptoethanol, were added to 0.5 ml of
0.1 mm sterile glass beads and shaken for 1 min three times, incubating
the samples on ice 1 min between pulses. The supernatant was recov-
ered after centrifugation. Cell-free extracts were analyzed by SDS–
PAGE (Laemmli, 1970); protein concentration was determined using
the BCA protein assay (Pierce).
2.8. Isolation and characterization of M. tuberculosis H37Rv GSK625-resis-
tant mutants
GSK625-resistant M. tuberculosis H37Rv mutants were isolated by
plating 108 CFU on Middlebrook 7H10 plates supplemented with 10%
OADC containing the compound at 20 μM(20xMIC). After 4weeks of in-
cubation at 37 °C, colonies were identified and purified through several
passages in inhibitor-containing plates. Single colonies were used to
amplify and sequence inhA alleles. DNAs of the 17 resistant mutants
were extracted from liquid cultures grown in Middlebrook 7H9 broth
supplementedwith 0.025% Tween 80 and 10% ADC. Onemilliliter of cul-
ture was centrifuged, and the pellet was resuspended in 500 μl of dis-
tilled water and incubated at 90 °C for 1 h and then filtrated by using
0.22 μm filters. Five microliters of the supernatant was used as a source
of genomic DNA for amplification of the inhA gene. PCRs of the entire
gene were performed for each mutant by using the PuRe Taq Ready-
To-Go PCR Beads kit (GE Healthcare Life Sciences). A 988-bp region
was amplified with the primers Forward (5′-
CAGCTTCCTGGCTTCCGAG-3′) and Reverse (5′-
TAACGTTCTCCAGGAACGG-3′), and PCR conditionswere an initial dena-
turation step of 5min at 94 °C, followed by 40 cycles of 30 s at 94 °C, 30 s
at 62 °C, and 3 min at 72 °C and ending with a final elongation step of
10 min 72 °C. PCR products were purified and sequenced using the
dRhodamine Terminator Cycle Sequencing Ready Reaction kit (Applied
294 M. Martínez-Hoyos et al. / EBioMedicine 8 (2016) 291–301Biosystems) in an ABI Prism 310 automated DNA sequencer (Applied
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2.9. Complementation experiments
Thewhole fabG1-inhA-hemH operon fromwild-type H37Rv andmu-
tants carrying the four mutant alleles (M103V, G96V, M103I, and
M103T) were cloned in the shuttle vector pSUM36(Ainsa et al., 1996).
M. tuberculosis H37Rv was transformed with the five plasmids and
transformants were selected using kanamycin and verified by colony
PCR using the PuRe Taq Ready-To-Go PCR Beads kit (GE Healthcare
Life Sciences). The sequences of the primers were as follows:
pSUM36_2, 5′-GTTGTGTGGAATTGTGAGCGG-3′; InhArev1, 5′-
GAAACGCGATCGACGAGTCGG-3′. The following thermocycler parame-
ters were used: an initial denaturation step of 9 min at 94 °C, followed
by 40 cycles of 30 s at 94 °C, 30 s at 64 °C, and 3min at 72 °C and ending
with a final elongation step of 10min 72 °C. Positive transformantswere
used MIC determination.
2.10. MIC determination against Mycobacteria
The antitubercular activity against extracellular of intracellularMy-
cobacterium strains was performed as previously described (Blanco-
Ruano et al., 2015).
2.11. MIC against clinical strains
The BACTEC MGIT 960 System (Becton Dickinson) was used to MIC
determination in clinical isolates (Institute Carlos III and Hospital Val
d'Hebron) following the manufacturer instructions.
2.12. General antimicrobial activity assay
Whole-cell antimicrobial activity was determined by broth
microdilution using the Clinical and Laboratory Standards Institute
(CLSI) recommended procedure, Document M7-A7 (Wikler, 2009).
Compounds have been evaluated against a panel of Gram-positive and
Gram-negative organisms, including Enterococcus faecium, Enterococcus
faecalis, Haemophilus influenzae, Moraxella catarrhalis, Streptococcus
pneumoniae, E. coli, and Streptococcus pyogenes. The MIC was deter-
mined as the lowest concentration of compound producing a reduction
in the observed fluorescence higher than 80%.
2.13. hERG inhibition determination and cell cytotoxicity assays
hERG Qpatch assay was described by Vasilyev et al. (2006)). Cell cy-
totoxicity assays was described by Crouch et al. (1993).
2.14. Kinetic solubility assay
Here, 5ml of 10mMDMSO stock solutionwas diluted to 100mlwith
phosphate-buffered saline, pH 7.4, equilibrated for 1 h at room temper-
ature, and filtered through Millipore Multiscreen HTS-PCF filter plates
(MSSL BPC). The eluentwas quantified by suitably calibrated flow injec-
tion CLND.
2.15. Cytochrome P450 (CYP450)
The P450 inhibition profile of the InhA inhibitors was determined as
previously described in reference (Kajbaf et al., 2011).
2.16. Tolerability studies
For tolerability studies C57BL/6 female mice of 18–20 gweight were
used (n = 6 mice). Drugs were administered as 1% methyl-cellulose
suspensions. The up-and-down method of experimentation is anadaptive procedure for conducting dose–response experiments having
yes/no end point. Animals are dosed one at a time at the best estimate
MNLD. The dose for each successive animal is adjusted up or down, de-
pending on the outcome of the previous animal. After reaching the re-
versal of the initial direction (the point where a decreasing dose
pattern requires an increase due a tested animal's survival or an increas-
ing dose pattern results in a decrease due to lethality), four additional
animals are dosed using the same up and down dose pattern. The max-
imal no lethal dose is calculated using the maximum likelihood algo-
rithm. If any animal died or acute clinical signs were noted, the up-
and-down procedure was carried out based on toxicological signs
(functional observational battery). According to the up-and-down sta-
tistical procedure based on if, two dose levels were determined; a
dose that caused adverse clinical signs to 5% of animals (SD05) and a
higher one that causes signs of toxicity at 95% of animals (SD95). Func-
tional observational battery (FOB) and bodyweight gain were recorded
and the animalswere killed 24 h and48 h after treatment andbloodwas
sampled by intra-cardiac puncture for clinical chemistry and hematolo-
gy analysis in He-Li tubes. Necropsy was carried out and the major or-
gans were weighed and preserved in formalin.
2.17. Microsomal fraction stability experimental procedure
Pooled mouse and human liver microsomes were purchased from
Xenotech. Microsomes (final protein concentration 0.5 mg/ml, 5 mM
MgCl2), and test compound (final substrate concentration 0.5 μM;
final DMSO concentration 0.5%) in 0.1 M phosphate buffer pH 7.4 was
pre-incubated at 37 °C prior to the addition of NADPH (final concentra-
tion 1 mM) to initiate the reaction. The final incubation volume was
600 μl. Control samples were included for each compound tested
where 0.1 M phosphate buffer pH 7.4 was added instead of NADPH
(minus NADPH). Midazolam was included as control in every experi-
ment. Each compound was incubated for 30 min and samples (90 μl)
were taken at 0, 5, 10, 20, and 30 min. The minus NADPH control was
sampled at 0 and 30 min only. The reactions were stopped by the addi-
tion of 200 μl of acetonitrile:methanol (3:1) containing an internal stan-
dard, followed by centrifugation at 3700 rpm for 15 min at 4 °C to
precipitate the protein. Quantitative analysis was performed using spe-
cific LC-MS/MS conditions. Data analysis: from a plot of ln peak area
ratio (compound peak area/internal standard peak area) against time,
the gradient of the line was determined. Subsequently, half-life and in-
trinsic clearance were calculated using the equations below:
Elimination rate constant kð Þ ¼ ‐gradientð Þ
Half life t1=2
 
minð Þ ¼ 0:693
k
Intrinsic clearance CLintð Þ ml=min=g tissueð Þ ¼ V  0:693
t1=2
where V = incubation volume ml/g microsomal protein and constant
used for mg microsomal protein/g liver is 52.5.
2.18. Killing kinetics assay
Bacteria were grown at 37 °C in 7H9 broth, 10% ADC, and 0.025%
Tyloxapol to mid-exponential phase and then diluted in 10 ml fresh
Middlebrook 7H9 to an 5 × 105 CFUs/ml. Incubation was continued
after the addition of compounds at 20xMIC. At specified time points, al-
iquots of cultures were withdrawn, serially diluted in 7H9 broth 0.025%
Tyloxapol and plated on solid culture medium. Plates were then incu-
bated at 37 °C and CFU were counted after 3 to 4 weeks.
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Time-lapse imaging of the GFP expressingMTB strain growing in the
custom-made microfluidic device was carried out as described before
(Wakamoto et al., 2013). Briefly, cells were grown in 7H9 medium at
37 °C to mid-log phase and were seeded into the microfluidic device
for imaging. Images were acquired at 1 h intervals on the phase and
FITC (Excitation 490/20; Emission 528/38) channels using a DeltaVision
personalDV imaging system (Applied Precision) equipped with a 100×
objective (Olympus UPLFL 100× PH, 1.3 NA) and a CoolSnap HQ2 cam-
era. Medium and compound were replenished every 24 h. As an end-
point assay, 1.0 μg/ml propidium iodide was added to the flow
medium for 24 h to stain cells with permeabilized cell envelopes and
imaging done on the red channel (Excitation 555/28; Emission 617/73).
Analysis of the time-lapse image stacks was carried out using ImageJ
v 1.47a (http://rsb.info.nih.gov/ij/). The survival curves depicted in Fig. 4
were generated by tracking cell division and lysis events over the course
of the experiment using the “Cell Counter” plugin of ImageJ. Cytolysis
was scored visually by abrupt loss of GFP fluorescence and abrupt de-
crease in phase intensity. Statistic analysis and fitting of data was per-
formed using Prism (GraphPad).
2.20. Mice
Specific Pathogen-free 6- to 8-week-old female C57BL/6j mice (18–
20 g) are obtained from Harlan (Harlan Interfauna Iberica, Spain). The
experiments were performed at AAALAC-accredited GlaxoSmithKline
Laboratory Animal Science animal facilities in Tres Cantos (Madrid,
Spain). The mice were kept in air-conditioned facilities with fifteen air
changes per hour. Room temperature and relative humidity were
22 ± 3 °C and 40–70%, respectively. The mice were accommodated in
groups of up to five individuals in Tecniplast® type IV cages with
autoclaved dust free corncob bedding (Panlab, Barcelona, Spain). The
mice were maintained under a 12-h light/dark period. Autoclaved tap
water and γ-irradiated pelleted diet were provided ad libitum.
2.21. Pharmacokinetic studies
Pharmacokinetic studieswere performed in C57BL/6j femalemice of
18–20 g weight (n=4mice per time point). Experimental compounds
were administered by intravenous route at 0.5 (GSK613 andGSK625) or
4 mg/kg (GSK693) single dose at a volume of 10 ml/kg and by oral ga-
vage at 50 (GSK613 AND 625), 100, 150, or 300 mg/kg single doses
(GSK693) at a volume of 20 ml/kg. All mice received treatment in the
fed state. Compounds were administered as solution in 1% DMSO, 7.5%
PEG400, and 20% Encapsine in saline for intravenous route and as 1%
methyl-cellulose suspension for oral route. Whole blood was the com-
partment chosen for the establishment of compound concentrations:
blood samples were taken by cardiac puncture for each mouse (eutha-
nized by CO2) at 5, 15, and 30 min, 1, 1.5, 2, 3, 4, and 8 h (n= 4 mice
per time point) for intravenous route and at 15, 30, and 45 min, 1, 1.5,
2, 3, 4, and 8 h (n = 4 mice per time point) for oral route. LC-MS was
used as the analytical method of choice for the establishment of com-
pound concentration in blood with a sensitivity of LLQ = 1–5 ng/ml in
25 μl blood. Thenon-compartmental data analysis (NCA)was performed
withWinNonlin 5.2 (Pharsight, Certara L.P), and supplementary analysis
was performed with GraphPad Prism 5 (GraphPad Software, Inc).
2.22. In vivo acute efficacy assessment
The experimental design has been previously described (Rullas et al.,
2010). In brief, mice were intratracheally infected with 100.000 CFU/
mouse (M. tuberculosis H37Rv). Products were administered for 8 con-
secutive days starting 1 day after infection. Lungs were harvested 24 h
after the last administration. For the chronic assay, mice were infected
with 100 CFU/mouse, and the products were administered daily(7 days aweek) for 8 consecutiveweeks starting 6weeks after infection.
All lung lobes were aseptically removed 24 h after the last administra-
tion, homogenized, and frozen. Homogenates were plated in 10%
OADC-7H11 medium for 14 days at 37 °C. Homogenates from com-
pound treatedmicewere incubated for 18days at 37 °C in plates supple-
mented with 0.4% (wt, vol) activated charcoal (Sigma Aldrich) to
prevent the effect of product carryover. Moxifloxacin (Sequoia Research
Products Ltd.) was prepared as solution in 20% Captisol(R)/water).
2.23. In vivo chronic efficacy assessment
Specific pathogen-free, 8- to 10-week-old female C57BL/6jmicewere
purchased from Harlan Laboratories and were allowed to acclimate for
1 week. In brief, mice were intratracheally with 100 CFU/mouse and the
products administered daily (7 days a week) for 4 or 8 consecutive
weeks starting 6 weeks after infection. Lungs were harvested 24 h after
the last administration. All lung lobes were aseptically removed, homog-
enized, and frozen. Homogenates were plated in 10% OADC-7H11 medi-
um supplementedwith activated charcoal (0.4%) for 18 days at 37 °C. The
positive control of isoniazid was assayed at 25 mg/kg, in distilled water.
3. Results
3.1. Biochemical, physicochemical, and ADME characterization of hits
GSK613 and GSK625
Several screening campaigns were run against InhA yielding an
overall hit rate of 0.63% after quencher removal. The campaign covered
a total of 1.9 million compounds unearthing GSK613 and GSK625 as the
most attractive representative structures of the thiadiazole series. Both
compounds exhibited a single-digit nanomolar activity in the enzyme
assay and micromolar in the whole-cell assay and showed selective an-
tibacterial activity againstM. tuberculosis. The physicochemical proper-
ties and preliminary ADMET profile were completed (Table 1) and used
to drive medicinal chemistry efforts.
N-(1-(2-chloro-6-fluorobenzyl)-1H-pyrazol-3-yl)-5-(1-(3-methyl-
1H-pyrazol-1-yl)ethyl)-1,3,4-thiadiazol-2-amine (GSK613) was
progressed to enzymatic mode of action studies to discard non-specific
enzyme inhibition. GSK613 is a selective (inactive against human FAS),
reversible inhibitor in addition to time, enzyme, and solvent indepen-
dent. Steady-state competition experiments have shown that the hit
competes with the fatty acid substrate for binding to the enzyme but
is uncompetitive with NADH, consistent with inhibitors binding to a
pre-formed enzyme:NADH complex (see Supplementary Fig. 1, Supple-
mentary Table 2).
3.2. Use of InhA overexpressor strain to confirmation whole-cell mode of
action
Two Mycobacterium smegmatis mc2155 and Mycobacterium bovis
BCG strains expressing increased levels of InhA protein from M.
smegmatis andM. tuberculosiswere constructed in order to identify in-
hibitors whose whole-cell activity is mediated mainly or solely by inhi-
bition of InhA (see Supplementary Fig. 2). A reproducible shift in the
minimum inhibitory concentration (MIC) values higher than or equal
to 4-fold in strains overexpressing the target was considered as indica-
tive that antitubercular activity is mainly mediated by InhA inhibition.
Thiadiazoles GSK625 and GSK613 met this criterion.
3.3. Structure of the InhA:GSK625 complex
Crystal structures were obtained for InhA in complex with NAD+
and the thiadiazole compound GSK625 at 2.9 Å resolution (see Supple-
mentary Table 1) (PDB ID 5JFO). The electronic density observed was
used for identifying the main scaffold and its disposition and interac-
tions within the active site (Fig. 1).
Table 1
Structure of hit compounds GSK613 and GSK625. Compounds were assessed for activity
against purified InhA,M. tuberculosisH37Rv, a panel of Gram-positive and Gram negative
bacteria, and HepG2 mammalian cells, ClogP, and DMPK parameters (in vitro and in vivo
clearance, volume of distribution at steady state (Vss), half-life (t1/2), Tmax, Cmax, and
dose normalized exposure (DNAUC) in mice).
InhA IC50 7 nM 2 nM
MtbMIC ≤1 μM 1 μM
Antibacterial
panel
≥64 μg/ml ≥64 μg/ml
MW 403.9 417.9
ClogP 3.75 4.05
Art. Memb.
Permeability
3.4 × 10−5 cm/s 5.4 × 10−5 cm/s
Solubility CLND 10 μM 9 μM
HepG2
cytotoxicity
Tox 50
N100 μM N100 μM
In vitro Cli
mouse
11.9 ml/min/g 14.9 ml/min/g
In vitro Cli
human
2.9 ml/min/g 2.8 ml/min/g
In vivo pharmacokinetic studies in mice
In vivo Cl
(0.5 mg/kg iv)
156.7 ml/min/kg 119.9 ml/min/kg
In vivo Vss
(0.5 mg/kg iv)
2.5 L/kg 1.5 L/kg
In vivo t1/2
(0.5 mg/kg iv)
0.3 h 0.2 h
In vivo Tmax
(50 mg/kg po)
0.75 h 1 h
In vivo Cmax
(50 mg/kg po)
94.3 ng/ml 2383 ng/ml
DNAUC
(ng·h/ml per
mg/kg)
5 123
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pocket of InhA, which was surrounded by residues M199, L207, I215,
M103, F149, Y158, A198, and I202 (residue numbering as in reference
(Lu et al., 2010; Rozwarski et al., 1999)). We were able to crystallize
the enzyme:inhibitor complex only in the presence of the cofactorFig. 1. X-Ray structure of InhA-GSK625 complex: Binding mode of GSK625 to the InhA active s
dashed lines), with G96, F97, M98, M103, F149,M161, I202, G104,M199, and L207 through hyd
M103, are colored in magenta. Atom coloring is oxygen red, nitrogen blue, sulfur yellow, chlorNAD(H), in agreementwith the uncompetitive character of these inhib-
itors relative to NADH (Fig. 1).When the structures of the InhA:GSK625
and that of the InhA:NAD+:C16-fatty acyl substrate analog complex
(Rozwarski et al., 1999) were compared, it was observed that the aro-
matic pyrazole ring of the inhibitor occupied the same pocket as the
thioester and the trans double bond of the C16-substrate analog, in
close proximity to NAD+, which is in agreement with the competitive
behavior of these inhibitors relative to the DDCoA substrate.
The pyrazole ring interacted with NAD+ via π-π stacking (4 Å). In
addition, the pyrazole nitrogen H-bonded to the 2′-hydroxyl of the ri-
bosemoiety in the cofactor (3.3 Å). The other key interactions identified
were the direct H-bonding between (i) the nitrogen of the thiadiazole
ring and the amide NH of Met98 and (ii) the nitrogen linking the
pyrazole and the thiadiazole rings and the carbonyl oxygen of Met98
(2.9 and 2.5 Å, respectively). Hydrophobic and van der Waals interac-
tions between the inhibitor and the side chains of the active site resi-
dues Met161, Phe97, Leu207, Met199, Met103, Gly 104, Met98,
Ala198, Gly96, Phe149, Tyr158, and Ile202 dominated the ligand–pro-
tein interactions. The halide substituted aryl ring of GSK625 interacted
with the main chain Met199, and Gly104, through its halogen atoms,
which increased the potency remarkably compared to the analogswith-
out the aryl moiety. Noticeably, the catalytic residue Tyr158 did not
make any H-bonds with the inhibitor and participated in ligand binding
through van der Waals interactions only (3.9 Å). Thus, GSK625 is a rep-
resentative of a class of inhibitors which does not need this conserved
network of interaction with Tyr158 for potency. Furthermore, in the
InhA:NAD+:GSK625 complex, the side chain of Phe149 adopted the
identical position as in InhA:NAD(H) structure.3.4. The thiadiazole series is bactericidal
To test if the these inhibitors shared the fast killingmode of action of
INH, we determined the in vitro killing rates of GSK625 at 20xMIC in
growth medium inoculated with approximately 106 bacteria, during
7 days (Fig. 2). After the first 2 days of incubation, the thiadiazole be-
haved similarly to INH, killing N99% of the initial bacteria. Due to the
high frequency of spontaneous resistance to INH, thenumber of bacteria
increases after 4 days of culture in presence of this drug, but not so in
cultures treated with GSK625, where the number of colony forming
units kept decreasing down to the detection limit.ite. GSK625 (green) interacted with NAD+ (gray) and M98 via H-bonds (shown as black
rophobic and van derWaals interactions. The two residues involved in resistance, G96 and
ine green, and fluoride light blue.
Fig. 2. Killing curve of GSK625. Killing rates ofM. tuberculosis, exposed to 20xMIC of GSK625, INH, and linezolid.
Table 2
Activity of thiadiazoles (GSK613, GSK625) and controls (kanamycin, InhA and ETH)
against M. bovis BCG overexpressing InhA.
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mutations map in the InhA active site
The in vitro rate of spontaneous resistance for GSK625 at 20xMIC
was 3.7 × 10−8 mutants/CFU, very similar to the frequency obtained
with rifampicin and three orders ofmagnitude lower than that for isoni-
azid (Zhang and Yew, 2009). This rate is consistentwith the presence of
a single defined target. GSK625-resistant mutants exhibited a shift in
MIC value by at least one order of magnitude and display no cross-resis-
tancewith other antitubercular compounds such as INH and rifampicin.
Since the compounds bind to the enzyme competitively with DDCoA, it
could be expected that mutations in the substrate-binding site could af-
fect the interaction of the thiadiazoles, while leaving isoniazid (INH)
and ethionamide (ETH) activity unaffected. The inhA alleles from single
colonies of the seventeen mutants were amplified and sequenced. Four
different pointmutationswere found in the coding regions from all mu-
tants, producing a single amino acid change at either of two positions:
Gly96 or Met103. These two amino acids map to the active site of the
enzyme (see Supplementary Table 3) and have not been reported to
be involved in resistance to InhA neither for isoniazid or ethionamide.
In order to link the point mutations in inhA to the resistant pheno-
type, the enoyl-ACP-reductase from the wild type and the four different
pointmutants were over-expressed and purified as untagged protein in
E. coli. All the mutated enzymes behaved similarly than the wild type
and a very good correlation between enzymatic IC50 for inhibition
with GSK625 and the MIC values of the source strains was observed
(see Supplementary Table 4). For the whole-cell analysis, the complete
inhA operon (fabG1-inhA-hemZ) from the wild-type H37Rv strain and
from the resistant mutants were cloned in a multicopy plasmid and
transformed in fast growingM. smegmatismc2155 and inM. tuberculosis
H37Rv. In all cases, the genetic transformation of the mutant operons
conferred resistance to thiadiazoles well above that obtained by ex-
pressing thewild type version from themulticopy plasmid (see Supple-
mentary Fig. 3).Wild
type −15 C/T inhA katG S315T
Compound/strain H37Rv CI1 CI2 CI3 CI4 CI5 CI6 CI7
GSK625
MIC (μM) 1 8 16 8 2 1 2 2
Ratio 1 8 16 8 2 1 2 2
INH
MIC
(μg/ml) 0.5 3.125 1.6 1.6 50 50 25 200
Ratio 1 6 3 3 100 100 50 4003.6. Activity of GSK625 against sensitive and M(X)DR M. tuberculosis clin-
ical isolates
InhA inhibitors, such as INH and ETH, have been in use for decades
and resistant MTB strains have emerged without identifiable mutations
in inhA or in any other studied gene (Sandgren et al., 2009). It wastherefore relevant to test a variety of clinical drug-resistant isolates for
the possibility of pre-existing cross-resistance to the thiadiazole class.
Two thiadiazole compounds were tested in a first instance against a
group of INH-resistant clinical isolates with characterizedmutations, ei-
ther in katG (themost frequent resistant class) or in nucleotide position
15 upstreamof the transcription start site for inhA (InhA overexpressor)
(Sandgren et al., 2009; Vilcheze and Jacobs, 2007). The compounds
retained full activity against the first group of mutants, while a moder-
ate shift (4–8 times) in MIC was observed against the group of strains
overexpressing InhA, as described above for laboratory constructs
(Table 2).
GSK625 has been tested against recent clinical isolates ofM. tubercu-
losis at two different TB reference centers (National Institute of Health
Carlos III, Madrid and the Supranational Reference Laboratory of the
Hospital Vall d'Hebron, Barcelona), and two observations were note-
worthy. The first onewas that theMIC90 obtainedwith 100 recently iso-
lated MTB stains is 3 μM, showing that the thiadiazole sensitivity of our
laboratoryH37Rv strain is representative for themajority ofMTB strains
isolated in Spain, which are therefore sensitive to the compound (see
Supplementary Table 5). The second was that GSK625 is active against
most resistant isolates present in the sample, with MIC values similar
to that of laboratory strain H37Rv independently of the resistance pro-
file of the clinical strains (see Supplementary Table 6).
3.7. Lead optimization summary, lead profile
Despite the interesting in vitro antitubercular profile stated above,
the initial hits were affected by a number of compound development li-
abilities such us physicochemical properties and DMPK profile. Further
medicinal chemistry efforts (details to be reported elsewhere) were
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efforts led to the identification of the chiral compound GSK693 as a
promising lead (Table 3).
GSK693 retained the enzymatic activity of previous GSK613 and
GSK625 hits. Additionally, GSK693 displayed equal potency against
theM. tuberculosis H37Rv inside and outside of macrophages (0.2 μM).
This was accompanied by a good CYP 3A4 inhibition profile. Early safety
assessment was carried out, across different enzymatic assays. GSK693
did not show any sign of cytotoxicty and nohERGpotassium channel in-
hibition (Vasilyev et al., 2006), suggesting a low risk for general toxicity
and cardiotoxicity. Genotoxocity alert was discarded with a full Ames
test (McCann et al., 1975). The breakthrough in the developability was
obtained with the decreased lipophilicity, the enhanced solubility, and
the reduced metabolic liabilities whilst simultaneously achieving good
mouse pharmacokinetic exposure levels after a single oral administra-
tion at different doses (see Supplementary Table 7). Cross-resistance
experimentswith previously isolatedmutants proved that the observed
TB activity for the lead compound was target related (data not shown).
Additional biological studies were carried out to confirm and gain fur-
ther insight into the mode of action of GSK693.
3.8. Single-cell analysis of effect of GSK693 on M. tuberculosis
To confirm that the synthesized derivatives retain the antitubercular
properties of the original hits, we evaluated the bactericidal activity of
GSK693 against MTB at the single-cell level by culturing the bacteria
in microfluidic devices and observing their behavior by time-lapse mi-
croscopy. MTB expressing GFP was grown in a microfluidic device for
6 days until they formed small microcolonies. The bacteria were then
exposed to 5 μM (2.1 μg/ml—25xMIC) GSK693 for 10 days, followed
by washout of the drug for 7 days. Exposure to GSK693 induced a
rapid growth arrest of individualMTB cells quite similar to the response
of MTB when exposed to INH. Interestingly, while in case of INH, the
cells continued to divide without elongation for several hours and
started to lyse after a lag of several days, in case of GSK693, the cell
lysiswasmore rapidwithout any significant lagperiod (see Supplemen-
tary Fig. 4).While the total fraction of cells undergoing lysis was compa-
rable between GSK693 (53 ± 20% N = 32 microcolonies) and INHTable 3
Structure and properties of optimized lead GSK693. The lead was assessed for activity
againstM. tuberculosisH37Rv both intra and extracellularly, physicochemical, and ADMET
properties.
Physchem properties MW 419.6
ClogP 0.71
Art. Memb. Permeability 1.9 ·10−5 cm/s
Solubility CLND 413 μM
Activity profile
InhA IC50 7 nM
MtbMIC 0.2 μM
Mtb intracell MIC 0.2 μM
Cytochrome P450 profile
CYP 3A4 IC50 VR N 50.1 μM
CYP 3A4 IC50 VG 25.1 μM
Cytotoxicity profile
HepG2 Cytotoxicity Tox 50 N50 μM
Cell Health (Memb.;
Nucleus; Mitoch. )
N199.5 μM
Genetic toxicity Ames test Negative
Cardiovascular profile Qpatch IC50 N50 μM
In vitro metabolic
stability
Cli mouse 2.1 ml/min/g
Cli human 0.2 ml/min/g
In vivo pharmacokinetic
study in mice
Cl (4 mg/kg iv) 83 ml/min/kg
Vss (4 mg/kg iv) 2.58 L/kg
t1/2 (4 mg/kg iv) 0.94 h
Tmax (100 mg/kg po) 0.42 h
Cmax (100 mg/kg po) 37,271 ng/ml
DNAUC 935.8 ng·h/ml per mg/kg(42 ± 15%, N = 41 microcolonies), the bacteriolysis induced by
GSK693 was significantly more rapid than INH (P = 0.011, log-rank
Mantel–Cox test). In both cases, after exposure to INH or GSK693, the
rate of killingwasmaintained even after washout of the drug, indicative
of strong post-antibiotic effect or long-term inhibition of the target by
the compounds. In order to identify cells that did not lyse visibly but
whose cellwallwaspotentially compromised,we stained the remaining
intact cells with propidium iodide (PI) as an end point assay. About 22%
of the cells still intact after GSK693 exposure were found to be PI-posi-
tive and remarkably the remaining 78% of the cells were still able to ex-
clude PI. None of the intact bacteria exhibited regrowth afterwashout of
the drug, possibly suggestive again of long-term target inhibition or
possible pushing of the surviving bacterial population into a non-repli-
cative senescent state.
3.9. Confirmation of KatG-independent activity of GSK693
As shown previously in Table 2, thiadiazole compounds exhibited no
change in MIC against INH-resistant clinical isolates carrying mutations
in katG. However, sinceMIC ismore of an assay of bacteriostatic activity,
we decided to confirm the katG-independent bactericidal activity of
GSK693. We compared the killing efficacy of INH vs GSK693 against a
panel of three strains differing in the level of KatG expression—(i) a
wild-typeM. tuberculosiswith the native katG locus; (ii) a katG-null mu-
tant ofM. tuberculosis, deficient in catalase activity (Ng et al., 2004); and
(iii) a katG-overexpressing strain ofM. tuberculosis that carries a second
copy of MTB katG at the atTB locus. These strains were exposed to
3.6 μM (0.5 μg/ml) INH or 5 μM of GSK693 for 4 days and the fraction
of bacteria surviving antibiotic treatment determined by plating. As ex-
pected, against INH, the katG-null mutant was resistant, and the katG-
overexpressing strain was more sensitive compared to the wild-type
strain (Fig. 3). Encouragingly and consistent with our previous observa-
tions, the katG-null mutant strain was killed equally well as the wild-
type strain byGSK693. This further reinforces the katG-independent na-
ture of bactericidal activity of GSK693.
3.10. In vivo efficacy of GSK693 in the acute and chronic TBmurine infection
models
Given its desirable and balanced profile, GSK693 fulfilled our re-
quirements to be progressed to tolerability and in vivo efficacy studies
in both acute and chronic TB murine infection models. The maximal
no lethal dose (MNLD) in mice was found to be higher than 1000 mg/
kg. Subsequently, the oral efficacy of GSK693 was evaluated in an
acute murine model as previously described (Rullas et al., 2010) at
doses of 30, 100, and 300 mg/K u.i.d. for 7 days, using moxifloxacin asFig. 3. GSK693 exhibits KatG-independent bactericidal activity. This plot depicts the
percent survival of wild-typeM. tuberculosis (WT); a katG-null catalase-deficient mutant
strain of M. tuberculosis (ΔkatG); and a katG-overexpressing strain of M. tuberculosis
(katG-2×) after exposure to 3.6 μM INH or 5 μM GSK693 for a period of 4 days. Data
shown represents the Mean + SE of three independent replicates.
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sponse pharmacological effect with this dose range (Fig. 4a). In mice
treated with 100 mg/kg, the bacterial load was reduced 4 log10 colony
forming units (CFU) per lung, matching the reduction obtained with
30 mg/kg of moxifloxacin.
The important proof-of-concept in vivo efficacy was obtained by
GSK693 in the acute murine TB model. GSK693 was further evaluated
in an established model of TB infection at a dose of 300 mg/kg as sus-
pension in 1%methylcellulose. After a 2-month treatment of chronically
infectedmice, GSK693 (300mg/kg) and isoniazid (25mg/kg), showed a
clear efficacy (Fig. 4b), and the differences observed between both
groups were not statistically significant.
The bacterial load reduction in both acute and chronic murine
modelswithGSK693 at 300mg/kg is virtually the same than the one ob-
served with isoniazid at the human equivalent dose.
4. Discussion
Isoniazid (INH) is togetherwith rifampicin the corner stone of the TB
treatment. It has been administrated to N40 million people saving mil-
lions of lives. Its outstanding cidal effect rapidly blocks bacterial spread
and significantly improves patient's conditions after a few weeks of
treatment.
On the basis of INHmode of action, it has been proposed that direct
inhibitors of the enoyl-ACP-reductase of Mtb can retain the outstanding
antitubercular profile of INH overcoming most of the issues associated
with the drug, such us drug resistance and toxicological effects. Addi-
tionally, compounds inhibiting InhA without requiring activation byFig. 4. (a) Dose–response studies in acute murine model of TB efficacy. Log CFU in mice
after oral treatment with different doses of GSK693 (30, 100, and 300 mg/kg) and
moxifloxacin at 30 mg/kg. Treatment in all groups resulted in a significant clearance of
bacilli compared with the controls (P b 0.001). (b) Efficacy response of GSK693 in
chronic, established murine model of TB infection. Log CFU in mice after oral treatment
with GSK693 at 300 mg/kg and INH at 25 mg/kg. Treatment in both groups resulted in a
significant clearance of bacilli compared with the controls (P b 0.001).KatG could be active under anaerobic conditions (Vilcheze et al.,
2011), where catalase-mediated activation is suppressed by the lack of
oxygen (Karakousis et al., 2008).
Following the above-mentioned rational, a biochemical assay based
on NADH consumption in the presence of docecenoyl-CoA by purified
InhA enzyme has allowed the identification of different direct inhibitors
of Mtb enoyl-ACP reductase. All the compounds showing IC50 values in
the micromolar range were clustered and tested for antitubercular ac-
tivity against wild-type and InhA overexpressor strains to identify five
chemical series of bona-fide inhibitors (whole-cell activity clearly
linked to enzymatic inhibition).
Enzymatic and whole-cell activities will provide the desired efficacy
at an acceptable dose, but a drug also needs to have the right physico-
chemical properties to increase the probability of success (Hann and
Keseru, 2012). The drug-like chemical properties of the selected InhA
inhibitors were evaluated to select thiadiazole series as the family
with the best balance between potency andphysicochemical properties.
GSK613 and GSK625 are the most attractive representative com-
pounds of the thiadiazole series. Both exhibited a single-digit
nanomolar activity in the enzyme assay and micromolar in the whole-
cell assay and showed a selective antibacterial activity againstM. tuber-
culosis. The series does not required KatG activation and retain the anti-
tubercular activity against sensitive, MDR, and XDR clinical isolates.
The in vitro frequency of spontaneous resistance is three orders of
magnitude better than the one obtained for isoniazid. The four different
point mutations identified conferring resistance were found in inhA
coding region, producing a single amino acid change at either of two po-
sitions: Gly96 or Met103. These two amino acids map to the active site
of the enzyme and have not been reported to be involved in resistance
to InhA neither for isoniazid or ethionamide.
Like other InhA direct inhibitors, thiadiazoles bind to the enzyme–
NADH complex, but in contrast to previously crystallized InhA inhibitors
such as pyrrolidine carboxamides (He et al., 2006), Genzyme10850, and
triclosan (Kuo et al., 2003), thiadiazoles do not establish any direct in-
teraction with Tyr158, and unlike the isoniazid-NADH adduct, GSK625
does not cause the flipping of the Phe149 side chain and thus there is
no interaction with the isonicotinic acid binding pocket.
Recently, it was proposed that high-affinity slow binding inhibition
of InhA is related to the ordering of the substrate-binding loop, brought
about by the long residence time of inhibitors on the enzyme (Lu et al.,
2010). Importantly, in all of the co-crystal structures with thiadiazoles,
the substrate-binding loop (residues 197–226) was ordered and well
resolved in the crystal structure, as previously seen with high-affinity
slow onset FabI inhibitor structures, implying that the compounds
may also be slow, tight binding inhibitors, which generally enhances
the in vivo activity and increases their potential as antitubercular drugs.
The medicinal chemistry efforts have been focused on the improve-
ment of the physiochemical properties andDMKprofile. GSK693 retains
all the antitubercular properties shown by the initial hits accompanied
by a good cytochrome P450 profile, lack of cardiovacular liabilities,
non-mutagenic, reduced lipophilicity, and good solubility which trans-
late to good oral bioavailability. Dosed orally as a 1% methyl-cellulose
suspension, the compound has shown a clear antitubercular activity in
the acute and chronic mouse models at free compound exposures sim-
ilar to those obtained with isoniazid.
5. Conclusion
Standard antitubercular treatment consists of a combination of four
compounds (isoniazid, rifampicin, ethambutol, and pyrazinamide) dur-
ing 2months that eliminate all the fast growing bacteria and 4 addition-
al months of isoniazid and rifampicin that complete patient cure.
The treatment is long, complex, and has important adverse effects,
so the lack of adherence is not unusual, leading to suboptimal responses
(failure and relapse), emergence of resistance, and continuous spread of
the disease. The presence of rapidly bactericidal compounds like
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mission and improving the health of infected people.
We have demonstrated that a direct inhibitor on InhA can retain the
outstanding profile of isoniazid and considering the DMPK parameters
of both compounds the antitubercular effect is achieved at similar expo-
sures of free drug proving our initial hypothesis and overcoming resis-
tances mediated by KatG. GSK693 has demonstrated in vivo efficacy
comparable to the marketed drug isoniazid without being a pro-drug,
thus overcomingmost of INH associated liabilities. Besides, its improved
property profile should translate into a safer treatment. Overall, this
achievement opens the door to the development of a direct inhibitor
of the enoyl-ACP reductase (InhA) as an attractive drug candidate for
the therapy of Tuberculosis.
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